Investegate |Algernon Pharmaceuticals Announcements | Algernon Pharmaceuticals: Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Investegate announcements from Algernon Pharmaceuticals, Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Related Keywords

United States ,Canada ,United Kingdom ,Netherlands ,Vancouver ,British Columbia ,American ,British ,Canadian ,Christopherj Moreau ,David Nutt ,Research Ethics Committee ,University Of New Mexico ,Algernon Pharmaceuticals Receives Approval For Groundbreaking Phase ,Algernon Pharmaceuticals ,Professor Of Neuropsychopharmacology At Imperial College London ,Constraint Induced Movement Therapy ,Leiden University ,Algernon Pharmaceuticals Inc ,Centre For Human Drug Research ,Leiden University Medical Center ,Neither The Canadian Securities Exchange ,Company Or Algernon ,Canadian Securities Exchange ,Algernon Pharmaceuticals Receives Approval ,Groundbreaking Phase ,Stichting Beoordeling Ethiek Biomedisch Onderzoek ,Medical Research Ethics Committee ,Human Drug Research ,Rick Strassman ,New Mexico ,Imperial College London ,Leiden Bio Science Park ,Constraint Induced Movement ,Market Regulator ,Investegate Announcements ,Investegate Company Announcements ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,